Guide to Selecting Vendors for Patient Support Programs
患者支援プログラムに最適なパートナーを評価・選定する方法をご紹介します。This…
Certara2025年10月20日
U.S. International Reference Pricing: Global Implications and Pharma Strategy
国際参照価格制度の意図せぬ世界的な影響：How the U.S. Most Favored Nation policy could…
Certara2025年10月6日
‘Most Favored Nation’ Policy Could Have Profound Impact on Global Drug Pricing if Fully Implemented
Editor’s Note: Jiwon Oh provided research support for this article. She is a Certara Market…
Certara2025年5月23日
Everything you need to know about ILAP 2.0
This white paper share’s key insights on the relaunch of MHRA’s Innovative Licensing and Access…
Certara2025年5月19日
Joint Clinical Assessment (JCA) And Potential Consequences For The Evaluation Of Gene Therapies
In October 2019, Galderma announced that the U.S. FDA approved AKLIEF® (trifarotene) Cream, 0.005% for the…
Certara2024年6月17日
Accelerating a drug launch with value communication technology and an integrated workflow
With early approvals for a targeted cancer drug in Brazil and Argentina, this global pharmaceutical…
Certara2023年10月2日
Using customer engagement technology to create value communication tools for ABILIFY MAINTENA® (aripiprazole)
Otsuka identified several weaknesses in their existing workflow for developing value communication tools. In particular,…
Certara2023年10月2日
Using Real-World Evidence to Derive an External Control Arm for a Rare Disease Drug Trial
Our client was developing a new anti-viral drug for a rare, life-threatening viral infection that…
Certara2023年4月17日
Using Real World Evidence to Inform Treatment Guidelines
Real-World Evidence (RWE) has become increasingly valuable in informing the development of treatment guidelines for…
Certara2023年4月5日
